Pinpoint Dx Lung Assay diagnostic data

Data from a pair of blinded validation studies in FFPE tumor samples from patients with non-squamous NSCLC showed that Pinpoint Genomics' Pinpoint Dx Lung Assay accurately identified patients at low-, intermediate- or high-risk of death within 5 years of surgical resection. Specifically, researchers at Kaiser Permanente Division of Research and colleagues reported data from FFPE tumor samples resected from 433 patients with stage I non-squamous NSCLC in a U.S. study showing that 5-year OS rates for patients in which the assay determined to be at low-, intermediate- and high-risk for early death were 71.4%, 58.3% and 49.2%, respectively (p=0.0003 for trend). Separately, researchers at the China Clinical Trials Consortium and colleagues reported data from tumor samples resected from 1,006 patients with stage I-III non-squamous NSCLC in a Chinese study showing that 5-year OS rates for patients in which the assay determined to be at low-, intermediate- and high-risk for early death were 74.1%, 57.4% and 44.6%, respectively (p<0.0001 for trend). ...